Mupirocin ointment composition, preparation method, application and related products

Abstract

The invention provides a mupirocin ointment composition, a preparation method, application and related products, and belongs to the technical field of external ointment. The mupirocin ointment composition provided by the invention is prepared from the following components in parts by weight: 0.5 to 5.0 parts of mupirocin, 58 to 68 parts of liquid polyethylene glycol, 20 to 36 parts of solid polyethylene glycol, 1.07 to 5.07 parts of borneol, 0.30 to 0.82 part of quercetin, 0.41 to 0.93 part of S-acetyl-L-glutathione and 0.7 to 3.2 parts of urea. The mupirocin ointment composition can be used for preparing the mupirocin ointment, and compared with the prior art, the mupirocin ointment has higher transdermal speed, intradermal retention volume and drug utilization rate, and is high in storage stability and good in biocompatibility.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of external ointment, and relates to a mupirocin ointment composition, a preparation method, application and related products. BACKGROUND

[0002] Mupirocin, English name Mupirocin, Chinese alias Mupirocin, Pseudomonas acid, Pseudomonas acid A. The chemical structure of Mupirocin is as follows: .

[0003] Mupirocin is a topical antibiotic anti-infective drug, and its antibacterial effect is mainly achieved by interfering with the synthesis of isoleucine-containing proteins in bacteria. Chen Shuying et al. in the article “Mupirocin in vitro sensitivity analysis of clinical isolates of Staphylococcus aureus” (Chinese Journal of Hospital Infection, 2016, No. 1, 23-25, 3 pages) pointed out that Mupirocin showed good in vitro antibacterial activity against Staphylococcus aureus, and the drug resistance rate remained relatively stable and low.

[0004] Chinese invention patent CN102335122A provides a mupirocin ointment, which contains the following components by weight percentage: 0.5-5% of mupirocin, 60-89 of polyethylene glycol 400, 10-36% of polyethylene glycol 4000 and 0.04-0.4% of organic acid. The preparation method of the above-mentioned mupirocin ointment is also disclosed. The technology improves the stability of the mupirocin ointment by using organic acid as a stabilizer, the related substances are low, and the clinical use has better efficacy.

[0005] Chinese invention patent CN114053210A provides a mupirocin ointment and a preparation method thereof, which comprises the following raw materials by weight: 30-70 parts of mupirocin, 300-400 parts of polyethylene glycol 3350, 700-800 parts of polyethylene glycol 400, 20-30 parts of propylene glycol, 10-30 parts of dragon blood extract, 8-22 parts of echinacea extract, 12-33 parts of butylated hydroxyanisole, and 11-28 parts of vitamin E oil. By matching and adding each raw material respectively, the stirring environment and conditions are controlled, so that the prepared mupirocin ointment has high content, good stability, no demulsification and crystallization, the active ingredients of the product are evenly distributed in the matrix, easy to apply, and meet the quality standard requirements.

[0006] However, the prior art cannot provide a mupirocin ointment with higher stability and better transdermal effect at a lower processing temperature. SUMMARY

[0007] Therefore, in view of the fact that the prior art cannot provide a mupirocin ointment with lower processing temperature, higher stability and better transdermal effect, the present application aims to provide a mupirocin ointment composition, a preparation method, an application and related products.

[0008] To achieve the above-mentioned application purposes, in one aspect, the present application provides a mupirocin ointment composition, which is composed of the following ingredients by weight: mupirocin 0.5-5.0 parts, liquid polyethylene glycol 58-68 parts, solid polyethylene glycol 20-36 parts, borneol 1.07-5.07 parts, quercetin 0.30-0.82 parts, S-acetyl-L-glutathione 0.41-0.93 parts and urea 0.7-3.2 parts.

[0009] Further, the mupirocin ointment composition is composed of the following ingredients by weight: mupirocin 1.2-3.8 parts, liquid polyethylene glycol 61-66 parts, solid polyethylene glycol 23-32 parts, borneol 1.51-4.89 parts, quercetin 0.37-0.69 parts, S-acetyl-L-glutathione 0.54-0.80 parts and urea 1.4-2.8 parts.

[0010] Still further, the mupirocin ointment composition is composed of the following ingredients by weight: mupirocin 2 parts, liquid polyethylene glycol 65 parts, solid polyethylene glycol 27 parts, borneol 2.67 parts, quercetin 0.56 parts, S-acetyl-L-glutathione 0.67 parts and urea 2.1 parts.

[0011] Still further, the liquid polyethylene glycol is at least one selected from polyethylene glycol 200, polyethylene glycol 400 or polyethylene glycol 600, and the solid polyethylene glycol is at least one selected from polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000 or polyethylene glycol 8000.

[0012] As an example of the present application, the liquid polyethylene glycol is polyethylene glycol 400, and the solid polyethylene glycol is polyethylene glycol 2000.

[0013] In another aspect, the present application provides a method for preparing a mupirocin ointment by using the above-mentioned mupirocin ointment composition, which comprises the following steps: S1, mixing S-acetyl-L-glutathione, quercetin, mupirocin, urea, borneol and ethanol, drying to obtain a drug-loaded body; S2, mixing 20%-30% of the liquid polyethylene glycol formulation by weight and controlling the temperature, and mixing the drug-loaded body obtained in step S1 to obtain a liquid containing the drug; S3, mixing the solid polyethylene glycol with the remaining amount of liquid polyethylene glycol under temperature control, and then mixing the liquid containing the drug obtained in step S2, and cooling to obtain the mupirocin ointment.

[0014] Further, in step S1, the drying is selected from freeze-drying or room temperature vacuum drying. As an example of the present application, the drying is freeze-drying.

[0015] Further, in step S2, the temperature control is to control the temperature to 40-60℃.

[0016] As an example of the present application, in step S2, the temperature control is to control the temperature to 50℃.

[0017] Further, in step S3, the temperature control mixing is specifically to warm to 65-70℃, mix evenly, and then cool to 45-48℃.

[0018] As an example of the present application, in step S3, the temperature control mixing is specifically to warm to 67℃, mix evenly, and then cool to 47℃.

[0019] In another aspect, the present application provides a mupirocin ointment made from the above-mentioned mupirocin ointment composition or the above-mentioned method.

[0020] In another aspect, the present application provides the use of the above-mentioned mupirocin ointment composition or the mupirocin ointment made by the above-mentioned method in the preparation of a medicament for treating skin infections.

[0021] In another aspect, the present application provides a medicament for treating skin infections, comprising the above-mentioned mupirocin ointment composition or the mupirocin ointment made by the above-mentioned method.

[0022] In the last aspect, the present application provides a dressing for treating skin infections, comprising the above-mentioned mupirocin ointment composition or the above-mentioned mupirocin ointment.

[0023] Compared with the prior art, the present application has the following beneficial effects: (1) In vitro transdermal effect experiment shows that the mupirocin ointment provided by the present application has a higher transdermal speed, a higher intradermal retention amount of mupirocin drug within 12h, and a higher drug utilization rate.

[0024] (2) Centrifugation experiment at 37℃ shows that the mupirocin ointment provided by the present application can maintain uniform, smooth and delicate, and easy to spread characteristics after centrifugation.

[0025] (3) Storage stability evaluation experiment shows that the mupirocin ointment provided by the present application has better storage stability under high temperature and high humidity conditions, higher content of active ingredient mupirocin, and lower content of mupirocin impurity C.

[0026] (4) Cytotoxicity experiment shows that the mupirocin ointment provided by the present application has good biocompatibility and no significant toxicity at 1000ppm. DETAILED DESCRIPTION

[0027] Terms and statements of the present invention: 1. The articles "a", "an", and "the": Unless otherwise expressly specified, include plural forms as well.

[0028] 2. Numerical ranges: Unless otherwise expressly specified, all ranges or ratios disclosed herein are to be understood to be inclusive of any and all sub-ranges or sub-ratios subsumed therein. For example, a stated range or ratio of 1 to 30 should be considered to include any and all sub-ranges or sub-ratios between the minimum value of 1 and the maximum value of 30, including by way of example only, 3 to 17, 4 to 10, 9 to 20, 6 to 18, 1 to 7, 20 to 30 and 23 to 28.

[0029] The following non-limiting examples can provide a more complete understanding of the application to one of ordinary skill in the art, but are not intended to limit the application in any way. The following examples merely provide further illustration of the scope of the application claimed, as those skilled in the art will be able to make numerous changes and modifications to the application based on the teachings provided herein.

[0030] The application is further described in the following non-limiting examples. The various chemical reagents used in the examples are obtained from commercial sources unless otherwise specified. The amounts recited in the following examples are understood to be amounts by weight unless otherwise specified. The following examples are conducted at room temperature (20-30°C) unless otherwise specified.

[0031] In the following specific examples, some of the reagents are obtained as follows in Table 1: Table 1

[0032] Examples 1-5 provide mupirocin ointment compositions having the following formulations (in parts by weight) as shown in Table 2: Table 2

[0033] Comparative Examples 1-5 provide mupirocin ointment compositions having the following formulations (in parts by weight) as shown in Table 3 ("-" means that the ingredient is not contained): Table 3

[0034] Preparation Example 1 The mupirocin ointment compositions of Examples 1-5 are used to prepare mupirocin ointment according to the following procedure: S1, S-acetyl-L-glutathione, quercetin, mupirocin, urea, borneol and ethanol were mixed according to the solid-liquid ratio of 1:10 g / mL, stirred uniformly, freeze-dried, and a drug-loaded body was obtained; S2, 25% of the formula weight of polyethylene glycol 400 was heated to 50°C, the drug-loaded body obtained in step S1 was added, and stirred and mixed uniformly to obtain a drug-containing liquid; S3, polyethylene glycol 2000 was heated to 67°C, the remaining amount of polyethylene glycol 400 was added, mixed uniformly, then cooled to 47°C, the drug-containing liquid obtained in step S2 was added, stirred uniformly, and cooled to room temperature to obtain the mupirocin ointment. The obtained mupirocin ointment is recorded as Example 1-Example 5.

[0035] Preparation Example 2 The method for preparing the mupirocin ointment using the mupirocin ointment composition of Example 1 is compared with Preparation Example 1, and the only difference is that in step S3, after the polyethylene glycol 2000 and the remaining amount of polyethylene glycol 400 are mixed uniformly, the temperature is not cooled to 47°C, but is maintained at the original temperature of 67°C, and the remaining steps are the same. The obtained mupirocin ointment is recorded as Preparation Example 2.

[0036] Preparation Comparative Example 1 The method for preparing the mupirocin ointment using the mupirocin ointment composition of Comparative Example 1 is as follows: S1, S-acetyl-L-glutathione, quercetin, mupirocin, urea, borneol and ethanol were mixed according to the solid-liquid ratio of 1:10 g / mL, stirred uniformly, freeze-dried, and a drug-loaded body was obtained; S2, 25% of the formula weight of polyethylene glycol 400 was heated to 50°C, the drug-loaded body obtained in step S1 was added, and stirred and mixed uniformly to obtain a drug-containing liquid; S3, polyethylene glycol 2000 was heated to 67°C, the remaining amount of polyethylene glycol 400 was added, mixed uniformly, then cooled to 47°C, the drug-containing liquid obtained in step S2 was added, stirred uniformly, and cooled to room temperature to obtain the mupirocin ointment. The obtained mupirocin ointment is recorded as Example 1-Example 5.

[0037] Preparation Comparative Example 2 The method for preparing the mupirocin ointment using the mupirocin ointment composition of Comparative Example 2 is as follows: S1, S-acetyl-L-glutathione, quercetin, mupirocin, urea, borneol and ethanol were mixed according to the solid-liquid ratio of 1:10 g / mL, stirred uniformly, freeze-dried, and a drug-loaded body was obtained; S2, 25% of the formula weight of polyethylene glycol 400 was heated to 50°C, the drug-loaded body obtained in step S1 was added, and stirred and mixed uniformly to obtain a drug-containing liquid; S3, heating polyethylene glycol 2000 to a temperature of 67℃, adding the remaining polyethylene glycol 400, mixing uniformly, then cooling to 47℃, adding the drug-containing liquid obtained in step S2, stirring uniformly, cooling to room temperature, to obtain the mupirocin ointment. The obtained mupirocin ointment is recorded as Comparative Example 2.

[0038] Preparation of Comparative Example 3 The method for preparing the mupirocin ointment using the mupirocin ointment composition of Comparative Example 3 is as follows: S1, mixing S-acetyl-L-glutathione, quercetin, mupirocin, urea and ethanol according to a solid-liquid ratio of 1:10 g / mL, stirring uniformly, freeze-drying to obtain a drug-loaded body; S2, heating 25% of the formula weight of polyethylene glycol 400 to a temperature of 50℃, adding the drug-loaded body obtained in step S1, stirring and mixing uniformly to obtain a drug-containing liquid; S3, heating polyethylene glycol 2000 to a temperature of 67℃, adding the remaining polyethylene glycol 400, mixing uniformly, then cooling to 47℃, adding the drug-containing liquid obtained in step S2, stirring uniformly, cooling to room temperature, to obtain the mupirocin ointment. The obtained mupirocin ointment is recorded as Comparative Example 3.

[0039] Preparation of Comparative Example 4 The method for preparing the mupirocin ointment using the mupirocin ointment composition of Comparative Example 4 is as follows: S1, mixing S-acetyl-L-glutathione, quercetin, mupirocin, urea and ethanol according to a solid-liquid ratio of 1:10 g / mL, stirring uniformly, freeze-drying to obtain a drug-loaded body; S2, heating 25% of the formula weight of polyethylene glycol 400 to a temperature of 50℃, adding the drug-loaded body obtained in step S1, stirring and mixing uniformly to obtain a drug-containing liquid; S3, heating polyethylene glycol 2000 to a temperature of 67℃, adding the remaining polyethylene glycol 400, mixing uniformly, then cooling to 47℃, adding the drug-containing liquid obtained in step S2, stirring uniformly, cooling to room temperature, to obtain the mupirocin ointment. The obtained mupirocin ointment is recorded as Comparative Example 3.

[0040] Preparation of Comparative Example 5 Compared with Preparation Example 1, the only difference is that the weight parts of each component are changed to those recorded in Comparative Example 5, and the rest are the same. The obtained mupirocin ointment is recorded as Comparative Example 5.

[0041] Comparative Example 6 The mupirocin ointment provided in Example 1 of the prior art CN113520994A.

[0042] Effect evaluation 1. Transdermal effect experiment evaluation 1.1. Construction and sampling of in vitro skin model.

[0043] SD rats (180-220 g) were anesthetized. The rat's abdominal hair was removed using a razor and depilatory cream (Veet). The rats were sacrificed 24 hours after waking up, and the whole abdominal skin after shaving was peeled off. Excess tissue was washed off with PBS, and the surface was dried. The skin tissue was wrapped in aluminum foil and stored at -20°C for later use.

[0044] 1.2. In vitro transdermal test.

[0045] One piece of skin tissue was placed in normal saline and thawed at room temperature. The surface of the skin was dried with filter paper. The skin was installed between the supply pool and the receiving pool of the Franz diffusion cell, with the stratum corneum facing the supply pool side and the dermis layer facing the receiving pool side. The effective area of the Franz diffusion cell was 3.14 square centimeters, and the receiving medium was PBS buffer solution with pH = 7.4. The receiving pool was filled with receiving medium, and the bubbles were discharged. The skin was kept at a constant temperature of 32°C for 40 minutes. The following groups of mupirocin ointment were precisely taken 0.1 g for the experiment: Mupirocin ointment of Example 1 group prepared in Preparation Example 1; mupirocin ointment of Preparation Example 2 group prepared in Preparation Example 2; mupirocin ointment of Comparative Example 1 group to Comparative Example 5 group prepared in Preparation Example 3; mupirocin ointment provided by the prior art in Comparative Example 6 group.

[0046] The obtained mupirocin ointment was carefully and evenly applied to the surface of the stratum corneum side. The Franz diffusion cell was placed in a transdermal diffusion instrument at a temperature of 32°C and a rotation speed of 250 rpm for transdermal experiment. 1 mL of receiving medium was taken out at 1h, 2h, 4h, 6h, 8h, 12h, respectively, and immediately supplemented with an equal volume of PBS buffer solution with pH = 7.4. The removed receiving medium was filtered using a filter membrane with a pore size of 0.22 μm, and the concentration of mupirocin in the solution was determined by HPLC method.

[0047] The cumulative transdermal flux of mupirocin per unit area was calculated according to the following formula.

[0048] Q=

[0049] Where Q represents the cumulative transdermal flux of mupirocin per unit area at the nth sampling point, C n represents the concentration measured at the nth sampling point, C i represents the concentration measured at the ith sampling point, V0 represents the volume of the receiving pool, V represents the volume of each sampling (1 mL), and A represents the effective permeation area (3.14 square centimeters).

[0050] After the experiment, the rat skin was taken off, washed with warm normal saline, dried at room temperature, crushed with a glass homogenizer, and then added with proper amount of methanol and ultrasonically extracted for 10 minutes. The filtrate was filtered through a 0.45 μm microporous filter. The filtrate was repeated for 3 times and combined. The content of mupirocin in the filtrate was analyzed by using HPLC method, and the skin retention amount was calculated.

[0051] Each group was detected in parallel for 5 times.

[0052] The experimental results of the cumulative penetration amount of mupirocin per unit area at the first sampling (1h), the cumulative penetration amount of mupirocin per unit area at the second sampling (2h), the cumulative penetration amount of mupirocin per unit area at the third sampling (4h), the cumulative penetration amount of mupirocin per unit area at the fourth sampling (6h), the cumulative penetration rate of mupirocin per unit area at the fifth sampling (8h), the cumulative penetration amount of mupirocin per unit area at the sixth sampling (12h), and the skin retention amount after 12h are shown in Table 4 (average value ± standard deviation, unit μg / cm 2 , n=5).

[0053] Table 4

[0054] It can be seen that the mupirocin ointment provided by Example 1 and Preparation Example 2 is superior to each of the comparative examples in terms of the intradermal retention amount at 12h.

[0055] The drug utilization rate was calculated according to the data in the above table.

[0056] Drug utilization rate = (average value of cumulative penetration amount per unit area at 12h + average value of intradermal retention amount of mupirocin per unit area at 12h) × penetration area ÷ total drug amount × 100%.

[0057] The penetration area is 3.14 square centimeters, and the total drug amount of each group is 0.1000g × 2% = 0.002g = 2000 μg.

[0058] Using the data in Table 4, the drug utilization rate of the mupirocin ointment of Example 1, Preparation Example 2, Comparative Example 1 to Comparative Example 6 within 12h can be calculated.

[0059] Using the same method, the mupirocin ointment prepared in Example 2, Example 3, Example 4 and Example 5 was tested and detected, and the drug utilization rate of the mupirocin ointment of Example 2, Example 3, Example 4 and Example 5 within 12h can be calculated. The experimental results of the drug utilization rate are shown in Table 5. Table 5

[0060] From the above experimental results, the mupirocin ointment provided by the present application can achieve higher transdermal speed, higher intradermal retention amount of mupirocin drug within 12 hours and higher drug utilization rate, and each component in the formula is indispensable. The specific weight ratio of quercetin, S-acetyl-L-glutathione, borneol and urea can form a microstructure wrapping mupirocin, which on the one hand accelerates the transdermal speed of mupirocin, and on the other hand can make the mupirocin component stay in the intradermal, thereby improving the utilization rate of the drug.

[0061] 2. Storage stability evaluation The mupirocin ointment was stored under the following three temperature and humidity conditions: 40℃, relative humidity 80%, storage for 15 days; 60℃, relative humidity 90%, storage for 15 days.

[0062] According to the related substance detection method recorded in the prior art CN102335122A, the actual percentage content (%) of mupirocin and the percentage content (%) of mupirocin impurity C of each group of mupirocin ointment were detected.

[0063] The chemical structural formula of mupirocin impurity C is as follows:

[0064] The actual percentage content (%) of mupirocin = the detected content of mupirocin (g / g) ÷ the prescription amount of mupirocin (g / g) × 100%.

[0065] The percentage content (%) of mupirocin impurity C = the detected content of mupirocin impurity C (g / g) ÷ the prescription amount of mupirocin (g / g) × 100%.

[0066] The detection results of the actual percentage content (%) of mupirocin are summarized in Table 6 below: Table 6

[0067] The detection results of the percentage content (%) of mupirocin impurity C are summarized in Table 7 below: Table 7

[0068] 3. Cytotoxicity experiment.

[0069] HaCaT cells were cultured, expanded and subcultured according to the standard culture method published on the official website of the American ATCC Biological Standard Resource Center. The cells were digested, resuspended and counted in the logarithmic growth phase of HaCaT cells, and diluted with complete culture medium (MEM+10% volume fetal bovine serum FBS+1% volume double-antibody solution) to a cell suspension concentration of 5×104 The cell suspension was prepared as follows: 1 mL of HaCaT cells were diluted with 9 mL of complete culture medium to obtain a cell suspension with a concentration of 1 x 105cells / mL. 100 μL of the cell suspension was added to each well of a 96-well plate, and the plate was incubated in a cell incubator (37°C, 5% CO2) for 24 h. The culture medium was carefully removed. 100 μL of a mupirocin ointment dilution prepared using complete culture medium was added to each well. The plate was again incubated in the cell incubator for 24 h. The culture medium was carefully removed. The cell survival rate (%) at different concentrations was detected using a CCK-8 kit (brand: Biyun Tian) and a microplate reader according to the method provided in the kit instructions. The average absorbance of the cells at a mupirocin ointment concentration of 0 ppm was taken as 1 for normalization. The detection results are shown in Table 8 (n = 4, mean ± standard deviation).

[0070] Table 8

[0071] It can be seen that, within the concentration range of 1000 ppm, the mupirocin ointments provided by the examples and the comparative examples did not exhibit significant toxicity to HaCaT cells.

[0072] Finally, it should be noted that the above content is only used to illustrate the technical solutions of the present application, and is not a limitation on the protection scope of the present application. Simple modifications or equivalent replacements of the technical solutions of the present application made by those skilled in the art do not deviate from the essence and scope of the technical solutions of the present application.

Claims

1. A mupirocin ointment composition, characterized in that, It consists of the following components by weight: Mupirocin 0.5-5.0 parts, liquid polyethylene glycol 58-68 parts, solid polyethylene glycol 20-36 parts, borneol 1.07-5.07 parts, quercetin 0.30-0.82 parts, S-acetyl-L-glutathione 0.41-0.93 parts, and urea 0.7-3.2 parts.

2. The mupirocin ointment composition according to claim 1, characterized in that, It consists of the following components by weight: Mupirocin 1.2-3.8 parts, liquid polyethylene glycol 61-66 parts, solid polyethylene glycol 23-32 parts, borneol 1.51-4.89 parts, quercetin 0.37-0.69 parts, S-acetyl-L-glutathione 0.54-0.80 parts, and urea 1.4-2.8 parts.

3. The mupirocin ointment composition according to claim 2, characterized in that, It consists of the following components by weight: 2 parts mupirocin, 65 parts liquid polyethylene glycol, 27 parts solid polyethylene glycol, 2.67 parts borneol, 0.56 parts quercetin, 0.67 parts S-acetyl-L-glutathione, and 2.1 parts urea.

4. The mupirocin ointment composition according to any one of claims 1-3, characterized in that, The liquid polyethylene glycol is selected from at least one of polyethylene glycol 200, polyethylene glycol 400, or polyethylene glycol 600, and the solid polyethylene glycol is selected from at least one of polyethylene glycol 1000, polyethylene glycol 2000, polyethylene glycol 4000, polyethylene glycol 6000, or polyethylene glycol 8000.

5. A method for preparing mupirocin ointment using the mupirocin ointment composition according to any one of claims 1-4, characterized in that, Includes the following steps: S1. Mix S-acetyl-L-glutathione, quercetin, mupirocin, urea, borneol and ethanol, and dry to obtain the drug-loaded body; S2. Mix 20%-30% of the liquid polyethylene glycol formulation by temperature control with the drug carrier obtained in step S1 to obtain a drug-containing liquid. S3. Mix the solid polyethylene glycol with the remaining liquid polyethylene glycol at a controlled temperature, then mix with the drug-containing liquid obtained in step S2, and cool to obtain mupirocin ointment.

6. The method according to claim 5, characterized in that, In step S1, the drying is selected from freeze drying or room temperature vacuum drying; in step S2, the controlled temperature is controlled to 40-60℃. In step S3, the temperature-controlled mixing specifically involves: heating to 65-70℃, mixing evenly, and then cooling to 45-48℃.

7. A mupirocin ointment, characterized in that, It is made from the mupirocin ointment composition according to any one of claims 1-4 or the method according to any one of claims 5-6.

8. The use of the mupirocin ointment according to claim 7 in the preparation of a medicament for treating skin infections.

9. A drug for treating skin infections, characterized in that, Includes the mupirocin ointment composition according to any one of claims 1-4 or the mupirocin ointment according to claim 7.

10. A dressing for treating skin infections, characterized in that, Includes the mupirocin ointment composition according to any one of claims 1-4 or the mupirocin ointment according to claim 7.

Images